New COPD Drug Trial Starts for Global Patients
A new Phase III study is evaluating an investigational drug for adults with COPD to help reduce severe exacerbations.
Updated on Oct. 30, 2026 in Asthma
Live Poll
Should pharmaceutical companies prioritize new research for chronic conditions like COPD?
Boehringer Ingelheim has initiated a global Phase III clinical trial to test the investigational drug verducatib in adults with COPD. The study aims to determine if this medication can reduce moderate to severe exacerbations for patients who typically experience neutrophil-driven inflammation.
Why it matters
COPD, which affects an estimated 213 million people globally, is the third leading cause of death, yet treatment options addressing underlying inflammatory drivers remain limited. This trial targets a significant portion of patients who do not fit the criteria for current eosinophil-focused therapies.
The global Phase III AIRWARD trial (NCT07907991) will enroll 1,800 adults across 450 sites to measure the annualized rate of moderate or severe COPD exacerbations over 52 to 76 weeks. These preliminary findings remain unproven, as the drug is still undergoing investigation.
The players
Boehringer Ingelheim
A pharmaceutical company focused on the development of novel therapies for respiratory diseases including COPD.
The details
Verducatib functions as a dipeptidyl peptidase 1 (DPP1) inhibitor. By inhibiting this enzyme, the drug targets the inflammation pathways often associated with neutrophils, which are thought to drive the condition in 60 to 90% of COPD patients. The trial specifically includes those with blood eosinophil counts below 300 cells/µL to focus on this patient subgroup.
Timeline
October 30, 2026: Boehringer Ingelheim officially registered the AIRWARD Phase III trial.
Health Landscape
This study is registered within the clinicaltrials.gov registry system as part of the broader effort to diversify COPD treatments beyond eosinophil-targeting therapies. It reflects an evolving focus on neutrophil-driven inflammation in chronic respiratory care.
While this trial represents a potential future treatment, verducatib is not currently available to the public. If you are managing COPD, it is worth discussing your current inflammatory profile and available maintenance therapies with your physician.
The takeaway
Researchers are investigating new ways to reduce the frequency of COPD exacerbations by targeting neutrophil-driven inflammation. Patients should continue their current prescribed management plans and consult with a specialist about new study enrollment opportunities.
Further reading
For more on the current standard of care and emerging research for chronic lung conditions, visit our Asthma section.
More information
View the complete AIRWARD clinical trial study details on the official registry.
Source note: This article includes information reported by The Manila times.
Live Poll
Should pharmaceutical companies prioritize new research for chronic conditions like COPD?
